- Home
- LIPO
as 07-26-2024 4:00pm EST
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | PITTSBURGH |
| Market Cap: | 3.5M | IPO Year: | 2022 |
| Target Price: | $2.00 | AVG Volume (30 days): | 56.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.36 - $2.71 | Next Earning Date: | 08-12-2024 |
| Revenue: | $477,449 | Revenue Growth: | 77.45% |
| Revenue Growth (this year): | -66.88% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Lipella Pharmaceuticals Inc. (LIPO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kaufman Jonathan H | LIPO | See remarks below. | May 14 '24 | Buy | $0.76 | 10,000 | $7,590.00 | 898,849 | SEC Form 4 |
| Kaufman Jonathan H | LIPO | See remarks below. | Mar 15 '24 | Buy | $0.79 | 30,000 | $23,649.00 | 863,849 | SEC Form 4 |
| Kaufman Jonathan H | LIPO | See remarks below. | Mar 15 '24 | Buy | $0.87 | 25,000 | $21,802.50 | 888,849 | SEC Form 4 |
Latest Lipella Pharmaceuticals Inc. News
LIPO Breaking Stock News: Dive into LIPO Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
GlobeNewswire
2 months ago
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
2 months ago
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Simply Wall St.
2 months ago
Lipella Pharmaceuticals First Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.19 loss in 1Q 2023)
GlobeNewswire
3 months ago
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
GlobeNewswire
4 months ago
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
GlobeNewswire
4 months ago
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
GlobeNewswire
5 months ago
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
Compare LIPO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LIPO Lipella Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.